Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Fremanezumab for Migraine Prevention
NCT03303105Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Dec 2017
- Primary completion
- Jun 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fremanezumab in migraine (2 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Percentage of Subjects With at Least One Treatment-Emergent Adverse Event at Day 562. Started Dec 2017; status: completed.
02
Drugs
fremanezumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT03303105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03303105.